

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 2

**Amendments to the Claims**

Please withdraw claims 35-42, 46, 48-68 and 74 without prejudice to applicants' rights to pursue the subject matter of these claims in this or a related application.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 3

1. (Original) A compound having the structure:



wherein

$\text{R}_1$  is present or absent, and when present is H,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkynyl,  $-(\text{CH}_2)_y\text{S}(\text{CH}_2)_x\text{CH}_3$ ,  $\text{C}_1\text{-C}_6$  aminoalkyl,  $\text{C}_1\text{-C}_6$  hydroxyalkyl or  $-(\text{CH}_2)_n\text{C}(=\text{O})(\text{C}_6\text{H}_4)(\text{CH}_2)\text{R}_2$ ;

$\text{R}_2$  is H or  $\text{C}_1\text{-C}_4$  alkyl;

$\text{R}_3$  is H or  $\text{C}_1\text{-C}_4$  alkyl;

$\text{R}_4$  is present or absent, and when present is H,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkynyl,  $-(\text{CH}_2)_y\text{S}(\text{CH}_2)_x\text{CH}_3$ ,  $\text{C}_1\text{-C}_6$  aminoalkyl,  $\text{C}_1\text{-C}_6$  hydroxyalkyl or  $-(\text{CH}_2)_n\text{C}(=\text{O})(\text{C}_6\text{H}_4)(\text{CH}_2)\text{R}_2$ ;

wherein n is an integer from 1-6;

wherein x is 0 or an integer from 1-5 and

y is an integer from 1-5, such that  $x+y < 6$ ;

at least one of  $\text{R}_1$  or  $\text{R}_4$  is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

the compound is charged when both  $\text{R}_1$  and  $\text{R}_4$  are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein at least one of  $\text{R}_1$  or  $\text{R}_4$  is  $-(\text{CH}_2)_n\text{C}(=\text{O})(\text{C}_6\text{H}_4)(\text{CH}_2)\text{R}_2$ .

Applicants: Jeffrey Sterling et al.


Serial No.: 10/718,879

Filed : November 20, 2003

Page 4

3. (Original) The compound of claim 1, wherein at least one of R<sub>1</sub> and R<sub>4</sub> is -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>.

4. (Original) The compound of claim 1, having the structure:



wherein

R<sub>1</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>4</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

at least one of R<sub>1</sub> or R<sub>4</sub> is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

the compound is charged when both R<sub>1</sub> and R<sub>4</sub> are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879


Filed : November 20, 2003

Page 5


5. (Original) The compound of claim 4, having the structure:



6. (Original) The compound of claim 4, having the structure:



7. (Original) The compound of claim 4, having the structure:



8. (Previously Presented) The compound of claim 4, wherein at least one of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl.

9. (Previously Presented) The compound of claim 4, wherein R<sub>1</sub> is absent and R<sub>4</sub> is present.

10. (Previously Presented) The compound of claim 4, wherein the chiral carbon is in the R configuration.

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 6

11. (Previously Presented) The compound of claim 4, wherein the chiral carbon is in the S configuration.

12. (Original) The compound of claim 9, wherein R<sub>1</sub> is absent and R<sub>4</sub> is methyl.

13. (Original) The compound of claim 7, wherein

R<sub>1</sub> is H or methyl;

R<sub>2</sub> is H or methyl;

R<sub>3</sub> is H or methyl,

or a pharmaceutically acceptable salt thereof..

14. (Previously Presented) The pharmaceutically acceptable salt of the compound of claim 1, wherein the salt is the chloride, mesylate, maleate, fumarate, tartarate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate or sulfate salt.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879


Filed : November 20, 2003

Page 7


15. (Original) The compound of claim 2 having the structure:




16. (Original) The compound of claim 1 having the structure:




17. (Original) The compound of claim 3 having the structure:




18. (Original) The compound of claim 3 having the structure:




19. (Original) The compound of claim 1 having the structure:



20. (Original) The compound of claim 2 having the structure:




21. (Original) The compound of claim 7, having the structure:




22. (Original) The hydrochloride salt of the compound of claim 21.

23. (Original) The compound of claim 7, having the structure:




24. (Original) The hydrochloride salt of the compound of claim 23.

25. (Original) The compound of claim 7, having the structure:



26. (Original) The hydrochloride salt of the compound of claim 25.

27. (Original) The compound of claim 7, having the structure:



28. (Original) The hydrochloride salt of the compound of claim 27.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003


Page 10

29. (Original) The compound of claim 5, having the structure:




30. (Original) The hydrochloride salt of the compound of claim 29.

31. (Original) The compound of claim 6, having the structure:



32. (Original) The hydrochloride salt of the compound of claim 31.

33. (Original) The compound of claim 4, having the structure:




Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 11

34. (Original) The compound of claim 4, having the structure:



35. (Withdrawn) A method for treating a subject afflicted with a neurologic disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, so as to thereby treat the neurologic disorder in the subject.

36. (Withdrawn) The method of claim 35, wherein the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

37. (Withdrawn) The method of claim 35, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.

38. (Withdrawn) A method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof so as to thereby treat multiple sclerosis in the subject.

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 12

39. (Withdrawn) The method of claim 38, further comprising administering to the subject a therapeutically effective amount of levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.
40. (Withdrawn) The method of claim 38, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.
41. (Withdrawn) The method of claim 35 wherein the therapeutically effective amount of the compound is administered by injection, systemically, orally or nasally.
42. (Withdrawn) A method for destroying or inhibiting the proliferation of microbes or fungus which comprises contacting the microbes or fungus with a composition comprising the compound of claim 1 and an acceptable carrier.
43. (Original) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
44. (Original) The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.
45. (Original) The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of glatiramer acetate.

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 13

46. (Withdrawn) A process for the manufacture of a pharmaceutical composition comprising admixing the compound of claim 1 with a pharmaceutically acceptable carrier.


47. (Original) A packaged pharmaceutical composition for treating a neurologic disorder in a subject comprising:

(a) the pharmaceutical composition of claim 43; and


(b) instructions for using the composition for treating the neurologic disorder in the subject.

48. (Withdrawn) A process of manufacturing the compound of claim 4 comprising the steps of:

(a) reacting



under suitable conditions with an amine exchanging agent in the presence of solvent to provide:



2 ;


(b) treating **2** with a chlorinating agent to provide

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003


Page 14




3

;

(c) reacting 3 with



to provide



wherein

R<sub>1</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and

(d) optionally alkylating the product of step (c), wherein R<sub>1</sub> is H, to provide the compound.

49. (Withdrawn) The process of claim 48, further comprising reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003


Page 15

are each H, with 2-bromo-4'-methylacetophenone in a polar solvent in the presence of a base to produce a compound having the structure:



50. (Withdrawn) The process of claim 49, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

51. (Withdrawn) The process of claim 48, further comprising reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with propargyl bromide in a polar solvent in the presence of a base to produce a compound having the structure:



52. (Withdrawn) The process of claim 51, wherein the polar solvent is acetonitrile and the base is potassium carbonate.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 16

53. (Withdrawn) The process of claim 48, further comprising reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with 2-chloroethyl methylsulfide in a polar solvent in the presence of a base, to produce a compound having the structure:



54. (Withdrawn) The process of claim 53, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

55. (Withdrawn) The process of claim 48, wherein the amine exchanging agent is a mixture of aqueous NH<sub>2</sub>NH<sub>2</sub> and hydrazinium sulfate in ethylene glycol.

56. (Withdrawn) The process of claim 55, wherein the chlorinating agent is SOCl<sub>2</sub>.

57. (Withdrawn) The process of claim 56, wherein R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl and R<sub>2</sub> and R<sub>3</sub> are H.

58. (Withdrawn) The process of claim 48, wherein the alkylating agent in step (d) is methyl iodide or dimethyl sulfate.


59. (Withdrawn) A process of manufacturing a compound having the structure:

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 17




wherein

R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl,

comprising reacting a compound having the structure:



with R<sub>1</sub>X in a polar solvent in the presence of a base, wherein X is a halogen atom, to produce the compound.

60. (Withdrawn) The process of claim 59, wherein the polar solvent is acetonitrile and the base is potassium carbonate.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 18

61. (Withdrawn) A process of manufacturing a compound having the structure:




wherein

$R_2$  is H or  $C_1-C_4$  alkyl; and


$R_3$  is H or  $C_1-C_4$  alkyl,

comprising,


a) reacting



under suitable conditions with a methylating agent, in the presence or absence of solvent to provide:



b) reacting the product of step a) with



Applicants: Jeffrey Sterling et al.


Serial No.: 10/718,879

Filed : November 20, 2003

Page 19

in the presence of p-toluenesulfonic acid to provide the compound.


62. (Withdrawn) The process of claim 61, wherein the product of step (b) is further alkylated with an alkylating agent to provide a compound having the structure:



63. (Withdrawn) The process of claim 61, wherein the methylating agent in step (a) is methyl iodide or dimethyl sulfate.

64. (Withdrawn) The process of claim 62 wherein the methylating agent is methyl iodide.

65. (Withdrawn) A process of manufacturing the compound of claim 19 comprising reacting a compound having the structure:



with propargylamine and p-TsOH in toluene to produce the compound.


Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003


Page 20

66. (Withdrawn) A process of manufacturing the compound of claim 18 comprising reacting a compound having the structure:




with propargylamine and p-TsOH in toluene to produce the compound.

67. (Withdrawn) A process of manufacturing the compound of claim 20 comprising reacting a compound having the structure:



with



in a polar solvent to produce the compound.

68. (Withdrawn) The process of claim 67, wherein the polar solvent is acetonitrile.

Applicants: Jeffrey Sterling et al.

Serial No.: 10/718,879

Filed : November 20, 2003

Page 21

Claims 69-73. (Canceled)

74. (Withdrawn) The method of claim 38 wherein the therapeutically effective amount of the compound is administered by injection, systemically, orally or nasally.